Two years out from the U.K.'s scheduled EU exit date, the life science sector is increasingly confident about its post-Brexit prospects.

Bristol-Myers Squibb will tap into the immuno-oncology expertise of the Parker Institute and Cancer Research Institute (CRI) in a bid to accelerate clinical…

Shares in Cerulean Pharma nosedived yesterday after the company agreed to sell off its anticancer assets at a bargain basement price and merge with Daré…

Pierre Fabre has teamed with an immuno-oncology spinout from the French Alternative Energies and Atomic Energy Commission to run drug discovery projects.

Heptares Therapeutics has struck a pain drug R&D pact with Daiichi Sankyo.

Galapagos has turned to Pharnext to identify low-doses of approved drugs that boost the efficacy of its pipeline prospects.

Horizon Discovery has struck a deal to evaluate cell line optimization technology developed by Amplycell.

Bioversys has enlisted Aptuit to support its efforts to identify and validate novel targets and drugs against Gram-negative bacteria.

Hospital group Sanford Health has invested $20 million in InGeneron to support clinical trials of a stem cell regenerative medicine.